Restore and maintain testosterone levels with AndroGel 1%
AndroGel 1% achieved steady-state testosterone levels within 2–3 days, which were maintained over 180 days.1
Baseline testosterone levels were 187.4 ng/dL for 100 mg AndroGel 1% (n=78) and 185.8 ng/dL for 50 mg AndroGel 1% (n=73)
- Patients (n=37) on 75 mg AndroGel 1% had a mean total testosterone concentration of 601 +/- 309 ng/dL on day 180.1
Randomized, multicenter (16 centers), parallel study comparing defined efficacy parameters of 50 mg and 100 mg AndroGel 1% and a testosterone patch in 227 hypogonadal men over a 180-day treatment period.
Patients on AndroGel 1% who had testosterone levels above or below the normal range on day 60 were titrated to 75 mg on day 91.3
- AndroGel 1% restored patients’ testosterone levels in the normal range within 24 hours and achieved steady state in 2–3 days.2
- 87% of patients who were appropriately titrated with AndroGel 1% (n=129) achieved an average serum testosterone level within the normal range on treatment day 180.2
- During the study, significant increases in hemoglobin/hematocrit and PSA levels occurred. Mean serum PSA concentration was shown to increase by 0.26 ng/mL (P<0.001) during the initial 6-month study with no further statistical increase from 6 months through 36 months. An increase in serum PSA levels occurred in approximately 18% of individual patients in a 3-year extension study.1,3,4
- Monitor serum testosterone, prostate-specific antigen, hemoglobin, hematocrit, liver function test, and lipid levels periodically.
AndroGel® (testosterone gel) 1% and 1.62% CIII are androgens indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone:
- Primary hypogonadism (congenital or acquired): testicular failure due to conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals.
- Hypogonadotropic hypogonadism (congenital or acquired): idiopathic gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation.
Important limitations of use:
- Safety and efficacy of AndroGel in males less than 18 years old have not been established.
- Topical testosterone products may have different doses, strengths, or application instructions that may result in different systemic exposure.
Important Safety Information1,5
WARNING: SECONDARY EXPOSURE TO TESTOSTERONE
- Virilization has been reported in children who were secondarily exposed to testosterone gel.
- Children should avoid contact with unwashed or unclothed application sites in men using testosterone gel.
- Healthcare providers should advise patients to strictly adhere to recommended instructions for use.
- AndroGel is contraindicated in men with breast cancer or known or suspected prostate cancer, and in women who are or may become pregnant, or are breastfeeding, as testosterone may cause fetal harm.
- Monitor patients with benign prostatic hyperplasia (BPH) treated with androgens due to an increased risk for worsening signs and symptoms of BPH.
- Patients treated with androgens may be at increased risk for prostate cancer and should be evaluated prior to initiating and during treatment with androgens. Monitor prostate specific antigen (PSA) levels periodically.
- Avoid unintentional exposure of women or children to AndroGel. Secondary exposure to testosterone can produce signs of virilization and should be brought to the attention of the healthcare provider. Exposure of a pregnant woman to AndroGel may result in potential hazard to the fetus. AndroGel should be promptly discontinued until the cause of virilization is identified.
- Increases in hematocrit, reflective of increases in red blood cell mass, may require lowering or discontinuation of testosterone. Monitor hematocrit prior to and periodically during treatment. Monitor hemoglobin periodically.
- AndroGel is not indicated for use in women.
- Treatment with AndroGel may lead to azoospermia; edema which may be serious in patients with preexisting cardiac, renal, or hepatic disease, or in patients taking adrenocorticotropic hormone (ACTH) or corticosteroids; gynecomastia; sleep apnea, especially in those with risk factors; changes in insulin sensitivity or glycemic control; and changes in anticoagulant activity.
- Treatment with androgens may lead to serious hepatic effects. AndroGel is not known to cause these adverse effects. Monitor liver function tests (LFTs) periodically.
- Changes in serum lipid profile may require dose adjustment or discontinuation of testosterone therapy. Monitor lipid concentrations periodically.
- Androgens should be used with caution in cancer patients at risk of hypercalcemia (and associated hypercalciuria). Regular monitoring of serum calcium concentrations is recommended in these patients.
- Most common adverse reaction of AndroGel 1.62% (incidence ≥5%) is an increase in prostate specific antigen (PSA). Most common adverse reactions of AndroGel 1% (incidence ≥5%) are acne, application site reactions, abnormal lab tests, and prostatic disorders.
- Dosage and administration for AndroGel 1.62% differs from AndroGel 1%. AndroGel is not interchangeable with other topical testosterone products.
Please see full Prescribing Information including BOXED WARNING and Medication Guide.
References: 1. AndroGel 1% [package insert]. 2. Swerdloff RS, Wang C, Cunningham G, et al. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab. 2000;85(12):4500-4510. 3. Wang C, Swerdloff RS, Iranmanesh A, et al; and the Testosterone Gel Study Group. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab. 2000;85(8):2839-2853. 4. Wang C, Cunningham G, Dobs A, et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab. 2004;89(5):2085-2098. 5. AndroGel 1.62% [package insert].